Phase 2 Melanoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any gender
• People who have given written consent before any trial procedures begin
• People who have been diagnosed through laboratory testing with melanoma that has spread within the skin or nearby tissue (called "in-transit metastases"), with or without spread to nearby lymph nodes
• People who have at least one tumour spot that measures 5mm or larger that can be measured
• People whose general physical health and ability to carry out daily activities falls within an acceptable range for this trial (confirm with trial site)

Who may not be able to join:

• People with a life expectancy of less than 6 months
• People who are unable to understand the trial information or follow the study procedures
• People who are pregnant or breastfeeding; women who could become pregnant must have a negative pregnancy test within 24 hours before receiving the study drug
• People who are unwilling or unable to use contraception for 5 months after treatment (women) or 7 months after treatment (men)
• People with serious heart conditions — such as unstable chest pain, a recent heart attack, significant irregular heartbeat, or severe heart valve disease — that would make general anaesthesia unsafe
• People with significant lung disease, such as severe chronic obstructive pulmonary disease (COPD), that would make general anaesthesia unsafe
• People whose kidney function is reduced beyond a certain level, as shown by blood test results (confirm with trial site)
• People with significantly reduced liver function, or a history of liver cirrhosis or high blood pressure in the liver's blood supply
• People with low white blood cell or platelet counts below specific levels (confirm with trial site)
• People with an active autoimmune disease — though some milder autoimmune conditions (such as vitiligo, type 1 diabetes managed with insulin, an underactive thyroid managed with hormone replacement, or psoriasis not needing systemic treatment) may still be considered eligible
• People with a lung condition called interstitial lung disease, or active non-infectious inflammation of the lungs
• People who need regular systemic treatment with corticosteroids above a certain dose, or other medicines that suppress the immune system, within 30 days of receiving the study drug (inhaled or topical steroids and certain low-dose replacements may be permitted — confirm with trial site)
• People who have an active infection currently being treated with systemic medicines
• People who have received a live vaccine within 30 days before the first treatment dose, or within 3 months after treatment
• People receiving certain other treatments at the same time, including some immunotherapy drugs, chemotherapy (other than a specific drug called melphalan used in isolated limb perfusion), other experimental therapies within 30 days before the trial, or within 3 months after trial treatment

Important: Always verify eligibility with the trial site directly before applying.